Homogeneous catalysis. transition metal based lewis acid catalysts.
作者:T. Keith Hollis、William Odenkirk、N.P. Robinson、John Whelan、B. Bosnich
DOI:10.1016/s0040-4020(01)87259-8
日期:1993.1
Transition metal basedLewisacids provide catalysts for the Diels-Alder and Mukaiyama reactions. These catalysts must possess an electron deficient axophilic metal center and a labile coordination position. Unlike traditional Lewisacids, those derived from transition metals can function in the presence of water and have welldefined structures. It is shown how a normally electron rich ruthenium atom
Homogeneous catalysis. A transition metal based catalyst for the Mukaiyama crossed-aldol reaction and catalyst deactivation by electron transfer.
作者:William Odenkirk、John Whelan、B. Bosnich
DOI:10.1016/0040-4039(92)89017-7
日期:1992.9
The cationic complex [Ru(salen)(NO)H2O]SbF6 is intrinsically a powerful catalyst for the Mukaiyama crossed-aldol reaction at 25°C in nitromethane solutions and at very low catalyst loadings but, for some reactions, electron transferfrom the silylenolether to the ruthenium catalyst can occur which leads to catalyst deactivation.
METHODS OF MAKING DIASTEREOMERIC ORGANIC COMPOUNDS
申请人:Fandrick Daniel Robert
公开号:US20140135493A1
公开(公告)日:2014-05-15
Disclosed is a process for making diastereomeric compound of the formula (I): wherein m, n and R
1
to R
4
are as defined herein. The process of the invention provides the compound of formula (I) in high yield and substantially free of the corresponding diastereomers. The compounds of formula (I) prepared by the process of the invention are useful for making pharmaceutically active compounds such as 11-β-hydroxysteroid hydrogenase type 1 (11-β-HSD1) inhibitors.
Methods of making diastereomeric organic compounds
申请人:Fandrick Daniel Robert
公开号:US08916701B2
公开(公告)日:2014-12-23
Disclosed is a process for making diastereomeric compound of the formula (I):
wherein m, n and R1 to R4 are as defined herein. The process of the invention provides the compound of formula (I) in high yield and substantially free of the corresponding diastereomers. The compounds of formula (I) prepared by the process of the invention are useful for making pharmaceutically active compounds such as 11-β-hydroxysteroid hydrogenase type 1 (11-β-HSD1) inhibitors.